GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] the FLOW rule is doing its job and people should stop complaining — 17 comments in the full submission. View in context.
438
c/trialwatch·submitted 1 year ago by u/anders_vermeulen

[Meta] the FLOW rule is doing its job and people should stop complaining

Readoutbranch of 6 comments

the FLOW rule is doing its job and people should stop complaining. Nothing about this affects the ranking maths, before anyone asks. On means, which this board treats as targets and which are nothing of the sort. A reported mean body weight change is the centre of a distribution that in these trials is very wide.…

Read the full submission and all 17 comments →

This branch

6 comments, started 1 year ago
u/tove_ogunleye9 points·1 year ago

open-label extensions are not the same evidence as the randomised phase

replysharereportpermalink
u/oskar_ibarra6 points·1 year ago

What did the confidence interval look like?

replysharereportpermalink
u/anders_vermeulen2 points·1 year ago

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/hedda_adeyemi1 point·1 year ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
[deleted]1 point·1 year ago

[deleted]

replysharereportpermalink
u/hugo_bergstrom1 point·1 year ago

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →